This study explores how urine proteomics (the study of proteins in urine) can predict blood pressure (BP) response in patients undergoing renal denervation (RDN). RDN is a treatment for hypertension (high blood pressure) that uses energy to disrupt nerves near the kidneys, helping to lower BP. However, not everyone responds the same to this treatment. By analyzing proteins in urine, researchers hope to identify who will benefit most from RDN.

Participants are adults aged 18-80 with high BP. They will undergo RDN and have their BP checked at the start and three months after the procedure. Urine samples will be collected for proteomic analysis to see if protein differences can predict BP response. The goal is better treatment selection.

• Participants must visit the clinic twice: baseline and 3 months after RDN.
• Study involves urine sample collection and BP measurements.
• Potential benefit: Personalized treatment plan for hypertension.